Stocky turns companies like Dermapharm Holding SE I into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. DMP.DE shows balanced but unremarkable fundamentals: a Value Compounder Score of 56/100 suggests modest profitability, while a 14.0 forward P/E reflects fair valuation with limited margin of safety. Growth Compounder weakness (47.5/100) indicates slowing expansion, and Leadership Alignment (52/100) lacks the founder-CEO ownership or capped dilution typically seen in compounders. Vulnerability is Adequate—financial cushion exists but offers little protection against operational headwind
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Dermapharm Holding SE I:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 49/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Dermapharm Holding SE I (DMP.DE) at 49/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. DMP.DE shows balanced but unremarkable fundamentals: a Value Compounder Score of 56/100 suggests modest profitability, while a 14.0 forward P/E reflects fair valuation with limited margin of safety. Growth Compounder weakness (47.
DMP.DE's current Stocky Verdict is 49/100, placing it in the "Cautious" band. This composite combines a 48/100 Compounder score, 52/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Dermapharm Holding SE I yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Dermapharm Holding SE I scores 52/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Dermapharm Holding SE I's Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Dermapharm Holding SE I.
Sign up free and unlock the full analysis on DMP.DE — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for DMP.DE in the app.
